FLT4 Antikörper (Extracellular Domain) (Biotin)

Produktnummer ABIN1589800

Dieser Maus Monoklonal Antikörper detektiert spezifisch FLT4 in WB, ELISA und IP. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für FLT4 Antikörper (Extracellular Domain) (Biotin) (ABIN1589800)

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser FLT4 Antikörper ist konjugiert mit Biotin

Applikation: Western Blotting (WB), ELISA, Immunoprecipitation (IP)

Klon: 1(9D9)

Produktdetails anti-FLT4 Antikörper (Biotin)

Bindungsspezifität: Extracellular Domain

Verwendungszweck: VEGFR-3/FLT-4 antibody

Spezifität: Recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain

Kreuzreaktivität (Details): The unconjugated antibody will detect native human VEGFR-3/FLT-4 in ELISA experiments.

Produktmerkmale: Chromosomal location: 5q35.3
The antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain. VEGFR-3/FLT-4 mediates the angiogenic activity of VEGF-C and VEGF-D on lymphatic endothelial cells.

Aufreinigung: The IgG1 fraction of the hybridoma supernatant was purified by Protein G affinity chromatography and then biotinylated using a standard protocol. VEGFR-3/FLT-4, belongs to the class III subfamily of receptor tyrosine kinases.

Immunogen: recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: WB: Use at 2-5 μg/mL, ELISA: Use at 1-10 μg/mL, IP: use at 2-10 μg/mL.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS, BSA (50x), 0.02 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Centrifuge vial prior to opening.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Haltbarkeit: 24 months

Details zu FLT4

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Andere Bezeichnung: VEGFR-3/FLT-4

Hintergrund: Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4,The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT-4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774). All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis.

Gen-ID: 2324

NCBI Accession: NM_002020

UniProt: P35916

Pathways: RTK Signalweg, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling